BuyersStrike!

It Was Dark Over Westphalia

Christmas Week Quick Take: What Misleading BS is Cytodyn Spewing Today? (CYDY)

What nonsense is everyone's favorite reverse-merger pink sheet Coronacrapper, **Cytodyn** (**CYDY**), spewing in this holiday-shortened, and retail trader dominated week? Today, the 22nd of December, comes a press release (https://www.cytodyn.com/investors/news-events/press-releases/detail/492/fda-resumes-eind-approval-for-severe-to-critical-covid-19) with a clearly misleading headline.

Notice the use of the word "**Approval**", which has a special meaning with regards to the FDA. INDs are never "approved", they are either rejected or accepted. **EINDs** (**Emergency INDs**) are never approved, they are "authorized". The use of "approval" in this context is **misleading**, as loserlimab (https://buyersstrike.wordpress.com/2020/08/28/but-teh-science-be-so-gud-part-1-a-brief-history-of-loserlimab-cydy/) has not been approved for anything by the FDA.

FDA Resumes eIND Approval for Severe-to-Critical COVID-19 Patients Use of Vyrologix™ (leronlimab) Following Full Enrollment in CytoDyn's Phase 3 Trial

December 22, 2020 6:00am EST **Download as PDF**

FDA's decision will enable CytoDyn to respond to ongoing requests for leronlimab until Phase 3 trial data is unblinded

(https://buyersstrike.files.wordpress.com/2020/12/eind-approvalpr.png)

You can read more about EINDs on the FDA's web site (https://www.fda.gov/drugs/investigational-new-drug-ind-application/physicians-how-request-single-patient-expanded-access-compassionate-use). What is important to note is that having an EIND accepted is neither noteworthy, nor newsworthy. It is a ho-hum, run-of-the-mill, everyday occurrence:

> Upon receipt of the single patient expanded access application, FDA will review to make a decision. The FDA will either allow the treatment to proceed or place the IND on hold. FDA allows over 99% of single patient expanded access requests to proceed. FDA may contact the physician to request more information or clarification in order to avoid placing the IND on hold.

(https://buyersstrike.files.wordpress.com/2020/12/fda-eind-acceptance.jpg)

What is newsworthy, however, is the Form 4 filed last night by **Cytodyn's** Klown Krew CFO **Mike Mulholland**, detailing the sale of millions of dollars worth of cheap stock. See the filing here. (https://www.cytodyn.com/investors/sec-filings/all-sec-filings/content/0001807094-20-000030/primary_doc.html?)

Common Stock	12/17/2020		M		32,000	A	$ 0.39
Common Stock	12/17/2020		S[1]		32,000	D	$ 4.5523 [2]
Common Stock	12/18/2020		M		155,500	A	$ 0.39
Common Stock	12/18/2020		M		233,100	A	$ 0.49
Common Stock	12/18/2020		M		98,402	A	$ 0.57
Common Stock	12/18/2020		S		487,002	D	$ 4.9516 [3]
Common Stock	12/21/2020		M		201,598	A	$ 0.57
Common Stock	12/21/2020		M		300,000	A	$ 0.80
Common Stock	12/21/2020		M		88,199	A	$ 0.87
Common Stock	12/21/2020		S		585,797	D	$ 5.582 [4]

(https://buyersstrike.files.wordpress.com/2020/12/mulholland4.png)

Cytodyn is obviously hoping the press release, and curiously timed companion puff piece article (https://www.zerohedge.com/news/2020-12-22/fda-should-restore-doctors-rights-use-medicines-work) by a tout (who happens to be affiliated with a paid promoter called "Streetwise Reports"), draws attention far far away from it.

[Did you know **Cytodyn** is being sued by a group of former directors? What to know why? Start here (https://buyersstrike.wordpress.com/2020/12/18/update-update-whos-suing-cytodyn-now-and-who-is-admitting-the-plaintiffs-are-right-cydy/) and here (https://buyersstrike.wordpress.com/2020/12/20/sunday-funday-what-else-doesnt-cytodyn-want-investors-to-learn-cydy/).]

Posted in Bad Directors, Bio-Dreck, Bucket Shops, CoronaCrap, Reverse Mergers on December 22, 2020 by BuyersStrike!. 3 Comments

3 comments

1. **Troy M** says:
   December 22, 2020 at 10:46 pm
   Lmao. The author of this is an idiot.

   [Can you point out a single inaccuracy Troy? Didn't think so. – **Editor**]

   REPLY
2. jbperez808 says:
   December 23, 2020 at 9:11 am
   "THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER."

   'NUFF SAID 🤣🤣🤣

   [Glad you are enjoying it. – **Editor**]

   REPLY
3. Pingback: Christmas Eve Quick Take: Who clearly has no clue what an Open Label Extension is? (CYDY) | BuyersStrike!